

Appl. No. : 09/625,049  
Filed : July 24, 2000

### AMENDMENTS TO THE CLAIMS

Claims 1-42. (Cancelled)

<sup>1</sup>  
Claim ~~43~~. (Previously presented) A multipurpose heterodimeric antibody derivative, comprising CL and VL domains interacting with CH1 and VH domains, said antibody derivative further comprising two or more other molecules having at least one further purpose coupled to two or more of said domains by a peptide bond at a C-terminus of the heterodimeric antibody, and wherein the heterodimerization is driven by the heterotypic interaction between the CH1-VH combination and the CL-VL combination of immunoglobulin domains.

<sup>2</sup>  
Claim ~~44~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein at least a first of the two or more other molecules is coupled to the CH1-VH chain and at least a second of the two or more other molecules is coupled to the CL-VL chain.

<sup>3</sup>  
Claim ~~45~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein the two or more other molecules are selected from the group consisting of: sFv molecules, toxins, enzymes, hormones, cytokines and signaling molecules.

<sup>4</sup>  
Claim ~~46~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~, wherein the coupling of two or more of said domains to the other molecules takes place via a linker.

<sup>5</sup>  
Claim ~~47~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~46~~, wherein the linker is an amino acid chain of at least 1 amino acid.

( Claim 48. (Cancelled) )

<sup>6</sup>  
Claim ~~49~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein a first other molecule is coupled to the C-terminal side of the CH1 domain and a second other molecule is coupled to the C-terminal side of the CL domain.

Appl. No. : 09/625,049  
Filed : July 24, 2000

Claim <sup>7</sup>~~50~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~49~~ wherein an sFv molecule is coupled to each of said CH1 and CL domains.

(Claims 51-60. (Cancelled))

Claim <sup>8</sup>~~51~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein said antibody is a multivalent antibody.

Claim <sup>9</sup>~~52~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein said antibody is a bispecific antibody.

Claim <sup>10</sup>~~53~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein said antibody is a trispecific antibody.

Claim <sup>11</sup>~~54~~. (Previously presented) The multipurpose heterodimeric antibody derivative according to Claim ~~43~~ wherein said antibody is a multispecific antibody.

Claim <sup>12</sup>~~55~~. (Previously presented) A pharmaceutical preparation comprising the multipurpose antibody derivative of Claim ~~43~~ and a pharmaceutically acceptable diluent.

Claim <sup>13</sup>~~56~~. (Previously presented) A diagnostic preparation comprising multipurpose heterodimeric antibodies according to Claim ~~43~~.

Claim <sup>14</sup>~~57~~. (Previously presented) A multipurpose heterodimeric antibody derivative, comprising CL and VL domains interacting with CH1 and VH domains, wherein said CH1 domain is not linked to a hinge region, said antibody derivative further comprising two or more other molecules having at least one further purpose coupled to two or more of said domains by a peptide bond at a C-terminus of the heterodimeric antibody, and wherein the heterodimerization is driven by the heterotypic interaction between the CH1-VH combination and the CL-VL combination of immunoglobulin domains.

Appl. No. : 09/625,049  
Filed : July 24, 2000

15  
Claim ~~68~~. (Currently amended) A multipurpose heterodimeric antibody derivative, comprising CL and VL domains interacting with CH1 and VH domains, wherein said CH1 domain is not linked to a hinge region, said antibody derivative further comprising according to claim 61, wherein the two or more other molecules are selected from the group consisting of: sFv molecules, toxins, enzymes, hormones, cytokines and signaling molecules coupled at an N-terminus of the molecules to two or more of said domains; and wherein the heterodimerization is driven by the heterotypic interaction between the CH1-VH combination and the CL-VL combination of immunoglobulin domains.

16  
Claim ~~69~~. (Previously presented) A multipurpose heterodimeric antibody derivative, comprising CL and VL domains interacting with CH1 and VH domains, wherein said CH1 domain is not linked to a hinge region, said antibody derivative further comprising two or more other molecules having at least one further purpose coupled to two or more of said domains, wherein a first sFv molecule is coupled to the C-terminal side of the CH1 domain and a second sFv molecule is coupled to the C-terminal side of the CL domain, and wherein the heterodimerization is driven by the heterotypic interaction between the CH1-VH combination and the CL-VL combination of immunoglobulin domains.